HKU ICB

Dr Albert Huang is Managing Director and Head of Healthcare Investment at Yunfeng Capital, Secretary-General of Tsinghua Alumni Association's School of Life Sciences and Medicine/Pharmaceuticals, and served as director of several biotech medical device, and diagnostic companies.

He has led the initiation and execution of projects in the biopharmaceutical, diagnostic, medical device industries, accumulating over a decade of experience in R&D, management, and investment in the healthcare sector. His deal experience includes privatization of WuXi AppTec (SH.603259) and the public offering of Tigermed (HK.3347), leading investments in innovative siRNA company-Brii Bio (HK.2137), acquiring one of the top 5 global cardiac pacemaker company Microport- Sorin, innovative dermatology company Cutia (HK.2487) and Giant Bio (HK.2367), biotech such as Abel Zeta / Sironax. He also managed and successfully exited the acquisition of in vitro diagnostic company ReLIA.

Educational background includes a Ph.D. in cellular pharmacology and stem cell research from Yale University and an bachelor of biology from Tsinghua University. He served as a project leader in the healthcare group at Boston Consulting Group (BCG). He was selected as one of "China's 36 Remarkable Investors" (36 Under36) by 36Kr and is on the F40 Investor list by Entrepreneur Magazine (40 Under 40). He also serves as adjunct lecturer at Tsinghua, SJTU, NYU Shanghai,